Rodrigo Sanchez Roger (@rodrogsan) 's Twitter Profile
Rodrigo Sanchez Roger

@rodrogsan

Medico Oncologo

ID: 571891754

calendar_today05-05-2012 16:40:35

2,2K Tweet

631 Followers

305 Following

Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

From foes to friends: rethinking the role of lymph nodes in prostate cancer out on Nature Reviews Urology nature.com/articles/s4158… The therapeutic value of lymph node removal in prostate cancer treatment is debated, as while it aids in disease staging, it may reduce the effectiveness of

Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

EAU-EANM- ESTRO -ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent out on European Urology europeanurology.com/article/S0302-… The 2024 European Association of Urology European Association of Urology (EAU) guidelines on clinically localized

Uromigos (@uromigos) 's Twitter Profile Photo

The Cancer Immunity Cycle has been updated! Listen to the details here as Ira Mellman breaks down this update. spotifyanchor-web.app.link/e/U3CbGVSIbMb

The Cancer Immunity Cycle has been updated! Listen to the details here as Ira Mellman breaks down this update.
spotifyanchor-web.app.link/e/U3CbGVSIbMb
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

1/ Results from #LITESPARK-005 are out <a href="/NEJM/">NEJM</a>! 
The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) <a href="/US_FDA/">U.S. FDA</a> approval Dec 2023 in pretreated pts w/ #ccRCC. 
Presentation #ESMO24 @myEsmo

Check it out: nejm.org/doi/full/10.10…
Asociación Argentina de Oncología Clínica (AAOC) (@aaoncoclinica) 's Twitter Profile Photo

CONVENIO AAOC - GRUPO GUIA La Asociación Argentina de Oncología Clínica y Grupo GUIA (Urooncología) firmaron los "Terminos y Condiciones del Acuerdo para el Sostenimiento de Actividades de Grupos Colaborativos" durante el Congreso de Estándares Terapéuticos 2024.

CONVENIO AAOC - GRUPO GUIA
La Asociación Argentina de Oncología Clínica y Grupo GUIA (Urooncología) firmaron los "Terminos y Condiciones del Acuerdo para el Sostenimiento de Actividades de Grupos Colaborativos" durante el Congreso de Estándares Terapéuticos 2024.
Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development annalsofoncology.org/article/S0923-…

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development 
 annalsofoncology.org/article/S0923-…
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Bladder-sparing therapy for BCG-unresponsive NMIBC should be personalized. Options include: Gemcitabine/Docetaxel, Nadofaragene Firadenovec, and Pembrolizumab, with consideration of efficacy and toxicity. ⭕️Radical cystectomy remains the gold standard. #BladderCancer #Oncology

Bladder-sparing therapy for BCG-unresponsive NMIBC should be personalized. 
Options include: 
Gemcitabine/Docetaxel, Nadofaragene Firadenovec, and Pembrolizumab, with consideration of efficacy and toxicity. 
⭕️Radical cystectomy remains the gold standard. #BladderCancer #Oncology
Katsuaki Maehara Ph.D. 🇯🇵 (@katsuakimaehara) 's Twitter Profile Photo

🫁 Lung Cancer - ICIs data 🫁 🌟 Summary of 5-year (long follow-up) data 🌟 NSCLC (NSQ & SQ) #Immunotherapy #Lungcancer #longfollowup #LCSM

🫁 Lung Cancer - ICIs data 🫁

🌟 Summary of 5-year (long follow-up) data

🌟 NSCLC (NSQ &amp; SQ)

#Immunotherapy
#Lungcancer
#longfollowup
#LCSM
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies & for steering drug development Annals of Oncology doi.org/10.1016/j.anno… 👏Excellent concept ESMO - Eur. Oncology

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies &amp; for
steering drug development
<a href="/Annals_Oncology/">Annals of Oncology</a> 
doi.org/10.1016/j.anno…
👏Excellent concept
<a href="/myESMO/">ESMO - Eur. Oncology</a>
Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG) #BladderCancer European Urology Oncology IBCG Ashish M. Kamat, MD, MBBS sciencedirect.com/science/articl…

⚡️Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG) 

#BladderCancer <a href="/EurUrolOncol/">European Urology Oncology</a>
<a href="/IBCG_BladderCA/">IBCG</a> <a href="/UroDocAsh/">Ashish M. Kamat, MD, MBBS</a> 

sciencedirect.com/science/articl…
Javier Milei (@jmileielecto) 's Twitter Profile Photo

A partir de hoy, las credenciales de los profesionales de la salud serán digitales, estarán disponibles en Mi Argentina y tendrán vigencia de cinco años.

A partir de hoy, las credenciales de los profesionales de la salud serán digitales, estarán disponibles en Mi Argentina y tendrán vigencia de cinco años.
Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification #BladderCancer OncoAlert nature.com/articles/s4158…

⚡️ Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification   #BladderCancer

<a href="/OncoAlert/">OncoAlert</a>
nature.com/articles/s4158…
Urooncologia.arg (@oncourologiaarg) 's Twitter Profile Photo

El próximo miércoles tendremos una gran sorpresa para la comunidad médica. 🩺🤫 Algo que marcará un antes y un después en Urooncología. ¡Estamos seguros que no te lo querrás perder! 🙌 #Próximamente #Atentos #AlgoGrandeViene #UrooncoArgentina

Urooncologia.arg (@oncourologiaarg) 's Twitter Profile Photo

Coming soon... El miércoles les compartiremos, a los #urologos y #oncologos de todo LATAM, una gran noticia! 🤭 #urooncology #urologia #oncologia #urooncoargentina